The clinical use of anti-Müllerian hormone (AMH) has increased exponentially due to its unique relationship with the ovarian reserve and ability to predict ovarian response, facilitate pretreatment counselling and individualize treatment strategies to minimize the risk of ovarian hyperstimulation syndrome. There is now a rapidly increasing literature examining additional possibilities for AMH, all of which suggest that its reach extends far beyond the assisted conception clinic. The recognition that it is a significantly more accurate and reliable measure of ovarian reserve than the antral follicle count or FSH has led to its adoption by physicians to counsel women on their reproductive lifespan, the impact of gonadotoxic chemotherapy, radiotherapy and surgery on the ovarian reserve and allow polycystic ovarian syndrome to be diagnosed by primary care physicians. We propose that there is an adequate literature base to embrace this technology while continuing to develop and refine how AMH can optimize patient care.

Anti-Müllerian hormone: clairvoyance or crystal clear? / Nelson, Scott M; Anderson, Richard A; Broekmans, Frank J; Raine Fenning, Nick; Fleming, Richard; LA MARCA, Antonio. - In: HUMAN REPRODUCTION. - ISSN 0268-1161. - STAMPA. - 27:3(2012), pp. 631-636. [10.1093/humrep/der446]

Anti-Müllerian hormone: clairvoyance or crystal clear?

LA MARCA , Antonio
2012

Abstract

The clinical use of anti-Müllerian hormone (AMH) has increased exponentially due to its unique relationship with the ovarian reserve and ability to predict ovarian response, facilitate pretreatment counselling and individualize treatment strategies to minimize the risk of ovarian hyperstimulation syndrome. There is now a rapidly increasing literature examining additional possibilities for AMH, all of which suggest that its reach extends far beyond the assisted conception clinic. The recognition that it is a significantly more accurate and reliable measure of ovarian reserve than the antral follicle count or FSH has led to its adoption by physicians to counsel women on their reproductive lifespan, the impact of gonadotoxic chemotherapy, radiotherapy and surgery on the ovarian reserve and allow polycystic ovarian syndrome to be diagnosed by primary care physicians. We propose that there is an adequate literature base to embrace this technology while continuing to develop and refine how AMH can optimize patient care.
2012
27
3
631
636
Anti-Müllerian hormone: clairvoyance or crystal clear? / Nelson, Scott M; Anderson, Richard A; Broekmans, Frank J; Raine Fenning, Nick; Fleming, Richard; LA MARCA, Antonio. - In: HUMAN REPRODUCTION. - ISSN 0268-1161. - STAMPA. - 27:3(2012), pp. 631-636. [10.1093/humrep/der446]
Nelson, Scott M; Anderson, Richard A; Broekmans, Frank J; Raine Fenning, Nick; Fleming, Richard; LA MARCA, Antonio
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1061858
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 90
  • ???jsp.display-item.citation.isi??? 76
social impact